摘要 |
<p>The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab')2 and Fv. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62.</p> |